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Abstract
Nowadays, pharmaceutical nanotechnology has been developed as the most emerging branch in the 
fi eld of pharmacy. “Nanotechnology refers to the nanosize formulation. These nanoformulations may be 
used in treatment of various life-threading diseases like cancer. Due to the advantages of their nano size 
and shape, nanoformulations have been shown to be favorable drug delivery systems and may be useful 
for encapsulating and conjugating of drugs, enabling most precise tumor targeting and controlled release. 
Nanoparticle drug delivery system have several advantages such as enhanced intracellular infi ltration, 
hydrophobic solubility, and drug circulation time and also reduce nonspecifi c uptake and toxic effect for 
cancer therapy. A large number of Nanoparticle technologies have been developed for cancer treatment 
to improve the therapeutic effi  cacy and safety for anticancer drugs. In this paper, we review the most 
signifi cant advancement in pharmaceutical nanotechnologies with methods of preparation and their use 
in drug delivery for cancer therapy.
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Introduction 
According to national nanotechnology initiative, 
Nanoparticles are structures of sizes ranging from 1 to 100 
nm in at least one dimension. Nanoparticles properties like 
physicochemical and biological are more easily taken up by cell 
than larger molecules, so Nanoparticles may be more suitable 
as drug delivery system [1]. 
Now days Nanoparticulate system gained more importance 
than conventional dosage form in cancer therapy because 
conventional dosage form have more challenge to deliver 
the drug in adequate quantity to the tumor site. While 
Nanoparticulate system may be possibility to deliver 
chemotherapeutic drug at target site easily [2].
Chemotherapeutic drugs are toxic to cancer cell but their 
high toxicity and low specifi city also destroyed the healthy 
cells. A possible strategy to overcome these problems or 
improve therapeutic effi cacy and decrease their toxic effect 
is called Nanoparticles technology [3]. The main object of 
these nanotechnologies is to transport proper amount of drug 
to desirable site and decreases toxic effect of drugs on other 
tissues [4].
In this review, we discussed Nanoparticles technologies 
and also focused on parameter for material selection for 
Nanoparticle and their advantages. These technologies include 
Liposomes, Polymer drug conjugates, Polymeric Nanoparticles, 
Micelle, Dendrimer, Polymersome, Protein Nanoparticles, 
Biological Nanoparticles, Inorganic Nanoparticles and Hybrid 
Nanoparticles.
Advantages of nanoparticles technologies in cancer the-
rapy 
Various studies show that Nanoparticles have ability to 
target to cancer cells without damaging healthy cells. So now 
a day Nanoparticles technologies are considered as superior 
drug delivery system in cancer therapy than other conventional 
dosage form. Target and enter into selective tissue at molecular 
level.
Increase cellular uptake and drug localization.
Accurate and selective drug delivery to cancerous cell 
without interaction with healthy cells
Providing large surface area
Providing high absorption rate
Less amount of dose required. 
Decrease drug resistance.
Decrease toxicity.
To improve the uptake of poorly soluble drugs
Nanoparticles can better deliver drugs to tiny areas within 
the body.
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Nanoparticles overcome the resistance offered by the 
physiological barriers in the body [5-7].
Factors affecting the selection of material for nanopar-
ticles preparation are 
Need of Nanoparticles size.
Drug properties such as stability and aqueous solubility
Desired drug release profi le
Required surface charge of Nanoparticles 
Biocompatibility and biodegradability
Toxicity and antigenicity of product [8].
Cancer is one of the most common problems and serious 
health issue in this world. Human body contains millions of 
tiny cells; these tiny cells are living units of the body. Cancer is 
a complex disorder that results from multiple genetic changes 
and cellular abnormalities [9]. Genetic changes that cause 
cancer can be, Inherited from our parents, Person’s lifetime 
and Environmental exposures such as chemicals in tobacco, 
smoke, radiation, ultraviolet rays from the sun [10].
Nanoparticles technologies
Liposome Nanoparticles: Liposomes were the fi rst 
Nanoparticles technology applied in medicine in 1961 [11]. 
Aim of liposomal drug delivery system to increase effi cacy, 
decrease toxicity and easy administration [12]. Liposomal 
Nanoparticles are most used Nanoparticles for cancer therapy, 
these are easily and self-assembled from amphiphilic lipid and 
excipients. The lipid part form a bilayer based on hydrophobic 
interaction with hydrophilic head groups. Hydrophobic drug 
molecules can be encapsulated in lipid bilayer and hydrophilic 
drug molecules can be encapsulated in aqueous phase [13]. 
Drug release from liposomes depends on composition, pH, and 
osmotic gradient and surrounding environment [14]. Lipids are 
used in these formulations are approved by FDA, that are DSPE 
(1, 2-distearoyl-sn-glycero-3-phosphoethanolamine), HSPE 
(hydrogenated phosphatidylcholine from soybean lecithin), 
EggPG (egg yolk phosphatidylglycerol), DSPC (1, 2-distearoyl-
glycero-3-phosphocholine). Liposome Nanoparticles have 
demonstrated multiple special benefi ts as drug delivery system, 
such as used to carry very potent drug to their low encapsulated 
load, instability in blood stream and poor solubility of many 
drugs. Many times researchers reported various challenges 
during the production of liposome are diffi cult reproducing 
formulation process, uniform particle size, effi cient drug 
loading, and time consuming process.
Types of liposomes: On the basis of phospholipid bilayer 
and the size of liposomes, these are following types [15-16].
Multilamellar Vesicles (MLV) -  these types of liposomes 
are contains multiple number of phospholipid bilayer member 
separated by aqueous phase. The size of multilamellar vesicle 
liposomes may up to 5 μm.
Small Unilamellar Vesicles (SUV) - these types of 
liposomes are contains single phospholipid bilayer member 
surrounding the aqueous phase. The of Small unilamellar 
vesicles liposome may be in the range of 20-100 nm.
Large Unilamellar Vesicle (LUV) - these types of liposomes 
are also contain single phospholipid bilayer member 
surrounding the aqueous phase. The of Small unilamellar 
vesicles liposome may be in the range of 100-250 nm.
Polymer drug conjugates nanoparticles
The concept of polymer conjugates for anticancer agent 
was proposed in 1975 [17]. Polymer drug conjugation achieved 
enhanced permeability and retention effect by tumor specifi c 
targeting [18].
Polymeric drug conjugation system is the most important 
and older polymeric drug delivery system. Polymer–drug 
conjugates are most advancement in the fi eld of Nanoparticles 
technology and currently in clinical trials phase III. These 
Nanoparticles can deliver high dose of chemotherapeutic drugs 
because in which drug conjugates with polymer through side 
chain. The size of polymer conjugates is below 20 nm mostly. 
The way of conjugating the drug to the Nanoparticles and its 
strategy is most important in cancer therapy. A drug molecule 
may be encapsulated in Nanoparticles or covalently attached 
to surface of Nanoparticles. Covalent attaching strategy had 
more advantages than other ways [19]. On the basis of various 
studies found that, application of Nanoparticles to tumor may 
be improved by the conjugated of polymer and drug moiety. 
These conjugations may allow more specifi c recognition and 
preferential interaction of drug to targeted tumor site [20].
Polymeric nanoparticles 
The purpose of polymeric Nanoparticles was to develop 
Nanoparticles for prolonged drug delivery system [21]. 
Polymeric Nanoparticles are fl exible in design because 
of polymer properties such as biodegradable and non-
biodegradable, synthetic and natural synthetic sources [22]. 
Commonly used polymers are poly (lactic acid) (PLA), dextran, 
and chitosan [23]. Polymer Nanoparticles can be used to 
improve the effi cacy, toxicity, bioavailability, solubility and 
pharmacokinetics of a drug. These particles may reduce toxicity 
in tumors and improved therapeutic response [24]. Polymeric 
Nanoparticles may offer encapsulation and delivery of bio-
molecules for genetic medicine, immunotherapy and gene 
editing. Polymeric Nanoparticles offer the various advantages 
in cancer therapy but during the development of these particles 
some challenges affect the safety and effi cacy of the polymer 
formulations [25]. These challenges are process scalability, 
process reproducibility, particle size control and effi cient drug 
loading. Drug can be encapsulated on polymeric Nanoparticles 
during polymerization step [26]. Drugs may be released 
from polymeric Nanoparticles by desorption, diffusion, or 
Nanoparticle erosion in target tissue [27].
Micelle nanoparticle
Micelles are self assemble Nanoparticles with hydrophobic 
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core composed from lipid and polymers. Micelles are the 
best drug delivery system for hydrophobic drugs. Only those 
chemical have an amphiphilic nature can form micelles in 
aqueous solution [28]. Micelles are generated when hydrophilic 
portions surrounding by hydrophobic phase. Micelles are 
most favorable drug delivery system for poorly water soluble 
drugs [29-31]. Pharmacokinetics properties of micelles 
were infl uenced by size of micelles Nanoparticles, generally 
accepted range of micelles is 50 – 150 nm, but larger the 
Nanoparticles size can carry more drug load because of high 
encapsulation volume [32]. Transport properties of micelles 
may be infl uenced by shape of micelles Nanoparticles. Discs 
and rod shape micelles have more accepted blood circulation 
properties than spherical particles [33].
Dendrimer nanoparticles
The word dendrimers derived from the Greek word 
“DENDRON” means tree and “MEROS” means part, so its 
appearance likes TREE. This technology discovered by Tomalia 
and coworker in early 1980. Dendritic polymers are newly 
recognized polymeric structure after linear, cross linked and 
branch polymer [34-35]. Dendrimers are repetitively branched 
molecules within the range of 5-10nm. They can be modifi ed 
as required to carry the drug for targeting site [36]. Dendimers 
serves suitable pharmacokinetic properties for systematic drug 
delivery. Structurally, dendrimers have three parts, namely a 
central core, tiers of multifunctional unit and terminal or end 
groups.
Dendrimers serves several properties those facilitated 
various biological applications as following [37-41].
Neutral and negative charge dendrimers are biocompatible 
while positive charge dendrimers may show toxic effects. 
Structure of dendrimers may affect pharmacokinetics 
properties.
Retention and bio-distribution character may improve by 
increase water solubility and size of dendrimers by PEGylation. 
Therapeutic agent can be attached to functional groups.
Can be modulated for target-specifi c drug delivery. 
Feasibility to develop with defi ned molecular weight. 
Good entrapment effi ciency.
Offering surface for functionalization. 
Very low polydispersity index. 
Very low size (1–5 nm).
Polymersome nanoparticles 
Structurally polymersomes are similar as liposomes 
but compositions are different, polymersome is composed 
of synthetic polymer/polypeptide amphiphiles and self-
assembled. Liposomes drug delivery system is the most widely 
used drug delivery system for anticancer drug moieties but 
their short half-life and slow drug release required to develop 
new alternatives. Synthetic polymers are most promising 
candidates to exhibit longer half-life and better drug release 
[42-44], when polymer and liposomes technology works 
together to design Nanoparticles are called polymersomes 
Nanoparticles [45-47]. Resulted polymersome Nanoparticles 
have been shown long half-life, better drug release, enhanced 
stability and more side chain functioning [48]. As liposomes, 
hydrophobic membrane and aqueous core of polymersome 
enables to encapsulate to both hydrophobic and hydrophilic 
drug moieties. Polymersome Nanoparticles technologies have 
ability to deliver both hydrophilic and hydrophobic drug in 
alone or combination [49].
Protein nanoparticles
Protein Nanoparticles are generally with 130 nm size. 
These particles bound drug with albumin to enhance intrinsic 
targeting abilities and permeability with retention effect 
at tumor site [50]. Protein Nanoparticles have gained great 
attention in nanotechnology because of their low toxicity, 
biodegradability, metabolizable and easy amenable to surface 
modifi cation for drug attachment [51]. Various types of 
proteins are used to prepare protein nanotechnology are water 
soluble proteins such as bovine, human serum albumin and 
insoluble proteins such as zein and gliadin [52-53]. The most 
important advantage of protein Nanoparticles as drug carrier 
system may target the drug by modifi ed body distribution and 
improvement of cellular uptake of the substances [54].
Biological nanoparticles
Biological Nanoparticles can be developed from organic and 
inorganic compounds based on natural biomolecules. Biological 
Nanoparticles derive from single or multiple assemblies of 
protein subunits [55]. These are unicellular microorganism 
with various shapes and sizes. Biological Nanoparticles have 
capacity to bind with both hydrophilic and hydrophobic drug 
molecule [56]. Biological Nanoparticles are divided in two 
categories are: a. delivery of small drug molecules for cancer 
treatment, b. gene therapy and vaccine applications. These 
systems are modifi ed by chemical or genetic modifi cation to 
achieve tumor specifi c delivery [57].
Inorganic nanoparticles
Various type of Nanoparticles are used as drug delivery 
such as silica Nanoparticles [58], quantum dots [59-60], metal 
Nanoparticles [61], and lanthanide Nanoparticles [62-63], 
Inorganic Nanoparticles are generally metal based particles. 
These may synthesized with near monodispersity. These 
Nanoparticles have ability to energy convert into heat at some 
specifi c conditions [64]. Metallic Nanoparticles are used as 
drug delivery system since last few decades but now days this 
technology is a favorable drug delivery system for anticancer 
drugs because these technology have various advantages such 
as effi ciency of drugs, biocompatibility, drug loading, nontoxic 
to normal cells and easily reached to targeted tumor sites. This 
technology used various metals to synthesized Nanoparticles 
like gold, silver, iron oxide. Gold Nanoparticles are synthesized 
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in various size range but commonly used ranges are 2-100 nm. 
Cellular uptake of these particles is inversely prepositional to 
their size and larger particle i.e. 80-100 nm does not diffuse 
in to tumor site and stay near the blood vessels [65-66]. 
These particle sizes depend on the thiol/gold ratio during the 
synthesis, as the thiol amount increases particle size decreases 
[67-68]. In this era various types of gold Nanoparticles take 
place in research such as gold nanoshells, gold nanosphere, 
gold nanorods and gold nanocages [69]. Another newest 
inorganic Nanoparticles technology for cancer therapy was 
developed as silver Nanoparticles.
Hybrid nanoparticles
Hybrid Nanoparticles are the advancement of liposome 
and micelles. These are composed of two different materials 
that form core and corona structure. Core contains metallic 
or polymeric material while corona contains lipid layer that 
worked as protecting membrane. As we have discussed in 
earlier in part of liposome that the drug moieties are attached 
on the surface of liposome or incorporated into hydrophilic 
phase to enhance retention time of drug to cancer cell. But at 
this time liposome decorated with paramagnetic molecules 
and enable to detection of angiogenesis [70-71]. So in these 
cases hybrid Nanoparticles technologies is required. Various 
types of inorganic material such as gold Nanoparticles and 
iron oxide Nanoparticles able to improve image contrast [72]. 
That’s by gold Nanoparticles and iron oxide Nanoparticles 
are encapsulated in liposome, hydrophilic gold Nanoparticles 
are encapsulated in hydrophilic phase and hydrophobic gold 
Nanoparticles are inserted in hydrophobic membrane.
Advancement of nanoparticle preparation methods
The mode of preparation of Nanoparticles plays a vital 
role to achieve the properties of Nanoparticles. The selection 
of these methods depends on the physical and chemical 
properties of drug and polymer. Scientist worked from ancient 
time to prepare Nanoparticles via various methods and their 
modifi cations, these methods and their modifi cations are 
listed below.
Emulsion-Solvent evaporation method
This method is widely used method for preparation of 
Nanoparticles. This method consist two steps a. emulsifi cation 
of polymer solution into water phase b. evaporation of solvent 
until Nanoparticle precipitation. Prepared Nanoparticles are 
collected by ultracentrifugation as washed with distilled water 
[73] (Figure 1).
Modifi ed Emulsion-Solvent Evaporation Method (Table 1).
Salting out method (Figure 2)
Modifi ed Salting Out Method (Table 2)
Solvent/emulsions diffusion method (Figure 3)
Modifi ed Solvent/emulsions diffusion method (Table 3)
Dialysis method (Figure 4)
ŵƵůƐŝĮcaƟŽŶ 
Step 1  
[OrgĂŶŝĐƐŽůƵƟŽŶ΁ 
PŽůǇŵĞƌ+ drƵŐŝŶ
watĞƌŶŽŶ miscible 
[AqueŽƵƐƐŽůƵƟŽŶ΁
StabilizĞƌŝŶwater 
^ŽůveŶt evĂƉŽraƟŽŶ 
Step 2 NaŶŽƉaƌƟĐůĞƐ 
Emulsion -Solvent Evaporation Method:  
Figure 1: Flow chart to prepare Nanoparticle using emulsion-solvent evaporation 
method.
Table 1: Modifi ed Emulsion-Solvent Evaporation Method.
S. No. Modifi cation Year
1
Modifi ed oil in water single emulsion solvent evaporation 
technique [74]
2014
2
Modifi ed by ratio of organic solvent, type of surfactant, type of 
polymers and the molecular weight [75]
2010
3
Changing the concentration of Stabilizer, polymer concentration, 
volume of aqueous Phase [76]
2004
4 High pressure emulsifi cation and solvent evaporation method [77] 2004
5 Double emulsion technique is employed, [78] 2002
6
Preparation of a emulsion which is then subjected to 
homogenization under high pressure followed by overall stirring to 
remove organic solvent [79]
2001
Polymer + drug in acetone [organic solvent] 
Stabilizer and salƟng out agent in water [aqueous phase] 
H2O 
Diīusion of acetone to aqueous phase 
NanopaƌƟĐůĞƐ 
Salting Out Method:  
Figure 2: Flow chart to prepare Nanoparticle using salting out method.
Table 2: Modifi ed Salting Out Method.
S.No. Modifi cation Year
1
Modifi ed as enhanced in temperature for heat sensitive substances 
[80]
2001
2
Technique used in the preparation of PLA, Poly( methacrylic) acids, 
and Ethyl cellulose nanospheres by modifi ed ratio [81]
2000
3
Technique used in the preparation of PLA, Poly( methacrylic) acids, 
and Ethyl cellulose nanospheres leads to high effi  ciency and is easily 
scaled up [82]
1998
4
Stirring rate, internal/external phase ratio, concentration of polymers 
in the organic phase, type of electrolyte concentration and type of 
stabilizer in the aqueous phase [83]
1993
[orgĂŶŝĐƐŽůƵƟŽŶ΁ 
Polymer + drug iŶƉĂƌƟĂlly 
water soluble solvent  
[AqueoƵƐƐŽůƵƟŽŶ΁ 
Stabilizer in water 
H2O 
Solvent eliminaƟon 
NanopaƌƟĐůĞƐ 
Solvent/emulsion diffusion method  
Figure 3: Flow chart to prepare Nanoparticle using solvent/emulsions diffusion 
method.
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Modifi ed Dialysis method (Table 4)
Precipitation method (Figure 5)
Modifi ed Precipitation Method (Table 5)
Patent fi lled by inventors to prepared nanoparticles
Researchers developed new formulations and their 
methods to achieve their goals, latest worked done by various 
researchers listed here (Table 6).
Conclusion 
As summarized above, new scientifi c approaches serves 
advanced technologies and overcome various challenges 
i.e toxicity, absorption, tumor site targeting, solubility, 
drug resistance, dose requirement etc. The ultimate goal of 
developing new technologies should be change the way of 
cancer treatment and overcome the challenges. Development 
of Nanoparticles drug delivery system is a future hope with 
great impact on cancer treatment approaches. Because 
researchers realize that Nanoparticles drug delivery may be 
stabilized to treat various type of cancer. Nanoparticles as 
drug delivery system are prepared to improve therapeutic 
and pharmacological properties of conventional drug delivery 
system. Drug molecule incorporated in Nanoparticles offers 
controlled release and possibilities to targeting to tumor site as 
well as protection of drug from degradation. Drug conjugations 
with Nanoparticles are more effective and selective and low 
toxic to healthy cells as well as required low therapeutic 
dose. Nowadays, various Nanoparticles based drug delivery 
is currently under preclinical evaluation phases. Some of 
Nanoparticle technologies have few limitations but these have 
possibility to improve with small modifi cations.
Table 3: Modifi ed Solvent/emulsions diffusion method.
S. No Modifi cation Year
1
Increasing homogenization speed from 6,000 rpm to 12,000 
rpm [84]
2012
2
Polylactic acid was used as the encapsulating polymer with 
acetone and ethyl acetate as organic solvents, and tween 20, 
gelatin and pluronic f68 in water as stabilizer. Two ratio of 
organic to aqueous phases were used with each solvent and 
stabilizer [85]
2011
3 Polymer used Cetyl palmitate [86] 2007
4
Modifi ed by used of coumarin to prepare Coumarin-loaded 
PLA Nanoparticles [87]
2005
5
Used mesotetra (hydroxyphenyl) porphyrin-loaded PLGA 
(p-THPP) to prepare nano particles [88]
2004
6
Cyclosporine (cy-A-); loaded sodium
glycolate Nanoparticlesused to prepareNanoparticle [89]
2002
7
Method modifi ed to prepare Doxorubicin-loaded PLGA nano 
particles [90]
1999
8
Modifi ed-SESD method using various solvent systems 
consisting of two water-miscible organic solvents, in which 
one solvent has more affi  nity to PLGA than to PVA and the 
other has more affi  nity to PVA than to PLGA [91]
1999
 
 
Polymer dissolve in organic solvent 
Placed in  
Dialysis tube  
Non solvent 
Nanoparticles 
Dialysis method  
Figure 4: Flow chart to prepare Nanoparticle using dialysis method.
Table 4: Modifi ed Dialysis method.
S. No. Modifi cation Year
1
Curcumin-loaded PLGA Nanoparticles was prepared through a 
modifi ed diffusion method [92]
2014
2 Modifi ed method used to prepare PLGA based Nanoparticles [93] 2014
3 Used poloxamer 188 and PLGA used to prepare Nanoparticle [94] 2013
4 Pullulan acetate As polymer used to prepare Nanoparticle [95] 2009
5
Using biodegradable poly (γ-benzyl-l-glutamate)/poly (ethylene 
oxide) (PBLG/PEO) polymer Nanoparticles. PBLG/PEO polymer is 
a hydrophilic/hydrophobic block copolymer and forms a micelle-
like structure in solution. Spherical Nanoparticles incorporating 
adriamycin were prepared by a dialysis method [96]
1999
 
[OrgĂŶŝĐƐŽůƵƟŽŶ΁ 
Polymer + drug + surfactant  
Stabilizer in water 
NanopaƌƟĐůĞƐ 
AqueouƐƐŽůƵƟŽŶ 
Solvent and residual Water evaporaƟon  
Precipitation method  
Figure 5: Flow chart to prepare Nanoparticle using precipitation method.
Table 5: Modifi ed Precipitation Method.
S. No. Modifi cation Year
1 Method modifi ed by using Fe II to particle growth process [97] 2014
2
Zinc oxide (ZnO) nano particles have prepared by using zinc nitrate 
and potassium hydroxide (KOH) in aqueous solution [98]
2012
3
Method modifi ed by using high-pressure homogenization with three 
important parameters, i.e. the agitation rate of stabilizer solution, 
homogenization pressure and cycle numbers [99]
2009
4
Method modifi ed by using poly(lactic acid) (PLA) and poly(d,l-lactic-
co-glycolic acid) (PLGA) as polymer solvent [100]
2005
5
Method modifi ed by using of poly (lactic acid) PLA, poly (lactic-co-
glycolic acid) PLGA and alginate [101]
1996
6
Method modifi ed to prepare cyclosporine-loaded poly D,L (lactide-
glycolide) (PLAGA) Nanoparticles [102]
1996
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Table 6: Patent Filled By Inventors to Prepared Nanoparticles:
Researchers developed new formulations and their methods to achieve their goals, latest worked done by various researchers listed here. 
S. No. Patent number Work done Reference
1 KR20180030493A
Inventor has prepared metal Nanoparticles using leaf or root extract of panax ginseng as active ingredients. Extraction has been 
done by hot extraction method. Metal Nanoparticles were prepared using a composition containing ginseng extract added to 
tetracholoro gold acid and silver nitrate solution of 1mM and maintained at 800C for 20 minutes and centrifuged at 16,000rpm 
to prepare the metal Nanoparticles. The size of prepared metal Nanoparticle was found to be 3-80nm mostly. But when using 
leaf extract and root extract Nanoparticles were found to be 10-20nm and 10-30nm respectively. Anticancer activity of prepared 
Nanoparticles was measured using MTT assay. Silver ginseng Nanoparticle exhibited cytotoxicity in 100㎍/ml for A549 lung 
cancer cells, gold Nanoparticles exhibited cytotoxicity in 2㎍/ mL concentration for A549 lung cancer cells.
[103]
2 KR20180036951A
Inventor has prepared metal Nanoparticles using extract of siberian ginseng as active ingredients. Extraction has been done by 
hot extraction method. Siberian ginseng extracts of various concentrations were used for the synthesis of metal Nanoparticles. 
1mM silver nitrate (silver nitrate; AgNO 3) or geumyeom hydrate (gold (III) chloride trihydrate; HAuCl 4 · 3H 2 O) to each other was 
added to the extract having a different concentration, and each production temperature (~ 230C, 400C depending on and 800C) and 
each manufacturing time to prepare the metal Nanoparticles. Then, the reaction mixture was centrifuged for 20 minutes at 17000 
rpm in order to obtain a prepared Sg-Sg-AgNPs or AuNPs. MTT asaay confi rmed the cytotoxicity against breast cancer line MCF7 
of prepared metal Nanoparticle.
(104)
3 CN108014346A
Inventor has prepared dual targeting Nanoparticles. Hyaluronic acid and octadecylamine and hyaluronate – octadecylamine 
(in combination) was dissolved in organic solvents in the presence of an activating agent. Methotrexate was added, reaction of 
methotrexate obtained - hyaluronic acid - octadecylamine conjugate, i.e. methotrexate prodrugs.  Then methotrexate prodrug of 
deionized water was treated with ultrasonic ice bath that results to self-assemble double targeted Nanoparticles within the range 
of diameter of 60 ~ 120nm. Hyaluronic acid acts as a targeting ligand, for Nanoparticles and shows synergetic effects.
[105]
4 KR20180014429A
Inventor has prepared carbon Nanoparticles using hydrothermal reaction.  Average size of prepared carbon Nanoparticle was 
found to be diameter of 2 nm to 20 nm. These Nanoparticles are coated with PEG, PEI. The resultant carbon Nanoparticles shows 
cytotoxicity to human cervical cancer line
[106]
5 CN107596384A
Inventor has prepared a self-targeted anti-cancer nano-particle. These self-targeted anti-cancer nano-particles are prepared by 
carboxylated metal oxide and an amido bond. Acetylated hyper branched polyethyleneimine is the active part which is bonded 
with Raltitrexed and has the mass content of 10 to 30 percent. These self-targeted anti-cancer nano-particles were loaded with a 
plurality of Raltitrexeds to form a multivalent system and shows high selectivity of cancer cells through strong bonding force of 
the receptor or multivalent system, and the toxicity of the Raltitrexed is utilized to specifi cally kill the cancer cells.
[107]
6 CN107281164A
Inventor has prepared EL PAMAM (G0) / HA and EL PAMAM (G1) / HAby using solvent exchange method. Prepared Nanoparticle 
such as EL PAMAM (G0) / HA and EL PAMAM (G1) / HA on HeLa showed no signifi cant cytotoxicity, cytotoxicity of A549 cells is 
stronger than in the HeLa cell cytotoxicity. A549 cells expression CD44 receptor, targeted drug erlotinib while nylon and non-small 
cell lung carcinoma A549 cells, it is toxic to A549 cells signifi cantly increased.
[108]
7 CN107041876A
Inventor has prepared anticancer acetylshikonin Nanoparticle. According to the inventor, acetylshikonin is loaded into graphene/
mesoporous silica and hyaluronic acid is used for plugging holes. The hyaluronic acid drug-loaded Nanoparticle enters into 
cancer cells release the acetylshikonin for killing the cancer cells with synergetic effects.
[109]
8 CN107158014A
Inventor has prepared co-assembled tumor targeting anti-cancer nano medicine. The carrier-free dual anti-cancer nano medicine 
is prepared from hydrophobic medicine ursolic acid, anti-tumor medicine doxorubicin in water through co-assembling. Prepared 
medicine shows the anticancer activity.
[110]
9 CN107375235A
Inventor has prepared a folic acid mediated antitumor drug super paramagnetic tumor targeted Nanoparticle. A super 
paramagnetic iron oxide Nanoparticle is used as the carrier. Polyethylene glycol-polyethyleneimine synthesized by high 
temperature decomposition method, and chemical method is used to grafted folic acid ligand on the surface of iron oxide. Then 
hydrogen bonding and electrostatic adsorption is used to loading anti tumor drug in to iron oxide Nanoparticles then obtaining 
the folic acid mediated antitumor drug super paramagnetic tumor targeted Nanoparticle. Inventor has fi nalized that, the prepared 
Nanoparticles shows synergetic anti tumor effect of anticancer drug.
[111]
10 CN107823183A
Inventor has prepared TiO2 Nanoparticles to overcome multidrug resistance. Inventor used the following method: by forming 
blank TiO2 Nanoparticles effective pH gradient, the anthracycline anticancer drugs into the package TiO2 Nanoparticles prepared 
anthracycline was obtained TiO2 Nanoparticles. Present invention is simple with improved effi  cacy of anthracycline anticancer 
drugs    and by wrapping techniques was used to overcome drug resistance. According to inventor present invention is simple, 
can delay the release of the drug in liquid culture, preparation of low material requirement, high encapsulation effi  ciency and   
effectively overcome MDR.
[112]
11 CN107758628A
Inventor has prepared Nanoparticles using aqueous extract of Camellia plants and nano selenium from selenium. Inventor has 
used following method: extraction of aqueous extract of Camellia plants is prepared, then reduced sodium selenite Vitamin C from 
extract in aqueous reaction occurs sol nano selenium. Selenium removal fom vitamin C has fi nished by nano particles. In vitro 
model was used to determine anticancer activity of prepared Nanoparticle of camellia extract.
[113]
12 CN107320459A
Inventor has prepared polymeric Nanoparticles based on double-layer synergistic controlled-release drug delivery. The 
preparation method comprises the following steps: fi rstly,   doxorubicin hydrochloride was embedded in oil phase of poly (N, 
N-dimethylaminoethyl) methacrylate, then loaded surface of oil phase with nitrosourea chloride, and then this system was 
embedding into aqueous phase and evaporating solvent to obtain polymeric Nanoparticles based on the double-layer synergistic 
controlled-release delivery system. The prepared Nanoparticles have achieved the controlled release of anticancer drug, and these 
used to treat cancer.
[114]
13 CN107929756A
Inventor has prepared amino wrapped porous silica Nanoparticles as drug delivery system. These Nanoparticles was dispersed 
in a drug solution, standing, centrifugation, and dried to obtain Nanoparticle drug system. These prepared Nanoparticles enable 
to release drug at high acidic condition. These Nanoparticles are prepared by following procedure, potassium ferricyanide was 
dissolved in hydrochloric acid at 50-1000C 15-20 hours, then centrifuged following by washed and dried to obtain Nanoparticles. 
Prepared Nanoparticles were used as drug delivery system.
[115]
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14 CN107551277A
Inventor has prepared lipid poly-L-histidine hybrid Nanoparticles (LPNs) encapsulating anti-tumor drugs with pH sensitivity. 
LPNs contain 50%-80% poly-histidine, and 20%-50% of lipid-PEG. Hydrophobic core of system consist poly-histidine and 
surface modifi ed with PEG and tumor targeted peptide. The PEGylated lipid surface has properties like high stability, good 
biocompatibility, and long in-vivo circulation. At neutral condition, histidine core enables to encapsulate hydrophobic anti cancer 
drugs. Histidine is protonized in the tumor microenvironment and change negative to neutral and then drug release rapidly with 
effective anti tumor activity. Surface of the carrier may change as require for tumor targeting to improve therapeutic effect.
[116]
15 CN107397958A
Inventor has prepared carbon quantum dots for anti cancer drug carrier. These quantum dots are prepared through the effect of 
citric acid, sulfuric acid, and nitric acid, Then sorafenib an anticancer drug was loaded in to carbon quantum dots. Then another 
emulsifi cation-solvent volatilization method was used to prepared drug loaded carbon quantum dots. Prepared carbon quantum 
dots Nanoparticles were used to treat cancer.
[117]
16 CN107970453A
Inventor has prepared pectin Nanoparticles with double folate targeted delivery. These Nanoparticles were conjugated with 
polyethylene glycol, pectin, folic acid and pectin have linked with amino bond, combination of polyethylene glycol and anti cancer 
drug via ester bond ursolic acid, to give folic acid ursolic acid prodrugs, mixed with captothecin, and then prepared self assembled 
dual targeting Nanoparticle. These Nanoparticles were show good in vitro release experiments of pH response.  Prepared dual 
targeting Nanoparticles serves high yield, controlled rate, as novel drug delivery for anti cancer drugs.
[118]
17 CN107753435A
Inventor has prepared paclitaxel - phospholipid / albumin Nanoparticles for cancer therapy. Inventor follows following steps: 1. 
Stock solution of paclitaxel, phospholipids, cholesterol and DSPE-PEG2000 2. Prepared paclitaxel liposome 3. Stock solution 
of bovine serum albumin and then Prepared paclitaxel - phospholipid / albumin complex Nanoparticles. Preparation method 
overcomes the drug aqueous solubility problems. Formulation has not used cremophor to avoiding side effect of solubilizer. 
DSPE-PEG2000 was added to increase stability, high encapsulation effi  ciency, small particle size, uniform particle size of 
Nanoparticles. Prepared Nanoparticles have studied as effective anti cancer drug delivery system.
[119]
18 CN107137721A
Inventor has discloses methods of preparation and polyoxometallate anticancer Nanoparticles. Polyoxometallates have high 
potential in cancer treatment as novel inorganic material but due to unstability and low aqueous solubility their uses in cancer 
treatment were limited. Inventors has used PLA-PEG2000, TPGS-COOH as coating material with biocompatibility to prepare a 
Nanoparticles, folic acid was used to modifi ed the surface of Nanoparticles, and prepared polyoxometallate supported anticancer 
Nanoparticles with long in vivo circulation, high targeting, low toxic effect and high stability. Prepared the polyoxometallate 
supported anticancer Nanoparticles were used to cancer therapy with fully achieved effects.
[120]
19 CN107050051A
Inventor has prepared cuprous oxide Nanoparticles of anticancer drug for treating gynecological tumors. In-vitro experiments 
of prepared cuprous oxide Nanoparticles were inhibit proliferation of cervical cancer cells and endometrial cancer cells. In vivo 
experiment was proved tumor inhibition effect of prepared cuprous oxide Nanoparticles equivalent to anticancer drug cisplatin 
with less side effects. Inventor has concluded that cuprous oxide Nanoparticles have great potential to treat gynecological 
tumors.
[121]
20 CN107737347A
Inventor has prepared dual target pectin, pectin - preparing multi-arm polyethylene glycol anti cancer drug. Nano folate multi-
arm polyethylene glycol-modifi ed prodrugs coupling stroke drug and pectin was target with dual drug, mixed certain ratio of 
hydrophobic anticancer drug, to obtain dual function Nanoparticle drug targeting. Used natural pectin has good biocompatibility, 
bioactivity,  biodegradability, overcome low aqueous solubility, prepared nano drug delivery system have good particle size 
distribution, stable rate of drug encapsulation effi  ciency and good clinical application..
[122]
21 CN106668871A
Inventor has prepared photosensitive magnetic Nanoparticle system enable to inhibited growth of breast cancer cells.  
Amiantion of magnetic Nanoparticles Fe3O4-OA wrapped by oleic acid and activating carboxyl on a photo sensitizer, then 
condensation reaction of amino and carboxyl to grafting the photo sensitizer onto the surface of Fe3O4-OA carboxyl to obtain 
the photosensitive magnetic Nanoparticle system. The photosensitive magnetic Nanoparticle system has used to treating 
breast cancer photo dynamically in illumination condition, combination of breast cancer targeting and folic acid cell targeting of 
a magnetic fi eld were inhibit growth of the breast cancer cells in a targeted manner. Prepared Nanoparticles have properties of 
high slow release performance, dispersity, stability and uniformity with low toxic and side effect advantages. Inventor has realize, 
prepared system was a novel administration path combining magnetic targeting with nano technology with high-effi  ciency low-
toxicity treatment effect.
[123]
22 CN107296794A
Inventor has prepared amphipathic non-steroidal anti-infl ammation platinum Nanoparticle. These Nanoparticles consists 
comprises an amphipathic compound formed by the non-steroidal anti-infl ammation drug and a platinum antitumor drug. 
Compared to others inventor prepared self assembled Nanoparticle in aqueous phase.  Without using the surfactant, amphipathic 
platinum compound can realize tumor tissue targeting with high permeability and low toxic effects of platinum drug. When these 
formulation enter in tumor site phagocytosis effect activated and releases two drugs under hydrolysis effect, anti-infl ammation 
drug can restrain COX-2, platinum drug  restrained  the tumor cell proliferation and collaboration of these two drug achieve the 
target of tumor treating.
[124]
23 CN107243000A
Inventor has prepared drug-loaded hybrid Nanoparticle. These hybrid Nanoparticles were prepared by following methods. 1. 
Prepared an azide triacetone compound 2. Prepared propargylamine modifi ed heparin sodium, 3. Grafted propargylamine 
modifi ed heparin sodium into the azide triacetone compound 4. Prepared drug-loaded hybrid Nanoparticle. These hybrid consist 
heparin as natural polymer with good biosafety and specifi c preparation process. Particle size of prepared hybrid Nanoparticles 
has enhanced permeability and retention effect, passive targeting and high drug release. Prepared Nanoparticles used for cancer 
therapy has good biocompat`ibility, low toxic effect with high safety.
[125]
Table 7: Newly Discovered Pharmaceutical Nanotechnology-Based Anticancer Drug Approved By FDA.
S.no. Drug Indication Mode of action Discovered by Reference 
1 Rucaparib (Rubraca)
For treatment of patients with deleterious 
BRCA mutation (germline and/or somatic)–
associated advanced ovarian cancer who have 
been treated with two or more chemotherapies.
Rucaparib inhibits "the contraction of isolated 
vascular smooth muscle, including that from 
the tumours of cancer patients. It also reduces 
the migration of some cancer and normal cells 
in culture
 Northern Institute of Cancer 
Research and Medical 
School of Newcastle 
University and Agouron 
Pharmaceuticals in San Diego, 
California. 
[126-127]
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2
Avelumab 
(Bavencio)
For the treatment of patient’s ≥ 12 years of 
age with metastatic Merkel cell carcinoma. 
Avelumab is a PD-L1 blocking human 
immunoglobulin G1λ monoclonal antibody. 
This is the fi rst FDA-approved product to treat 
this type of cancer.
Binds to the programmed death-
ligand 1 (PD-L1), inhibits binding to its 
receptor programmed cell death 1(PD-1) 
 Merck KGaA and Pfi zer and Eli 
Lilly and Company in Canada
[128]
3 Niraparib (Zejula)
Maintenance treatment for adult patients 
with recurrent epithelial ovarian, fallopian 
tube, or primary peritoneal cancer who are in 
complete or partial response to platinum-based 
chemotherapy.
 Inhibitor of the enzymes PARP1 and PARP2 
Tesaro, Waltham, massachusetts [129]
4 Ribociclib (Kisqali)
In combination with an aromatase inhibitor 
as initial endocrine-based therapy for the 
treatment of postmenopausal women with 
HR-positive, HER2-negative advanced or 
metastatic breast cancer.
Inhibitor of cyclin D1/CDK4 and CDK6
 Novartis and Astex 
Pharmaceuticals 
[130]
5 Brigatinib (Alunbrig
For treatment of patients with metastatic 
anaplastic lymphoma kinase– positive NSCLC 
who experienced disease progression on or 
who are intolerant to crizotinib
Inhibitor of ALK and mutated EGFR  ARIAD Pharmaceuticals, Inc [131]
6
Midostaurin 
(Rydapt)
For treatment of adult patients with newly 
diagnosed AML who are FLT3 mutation–
positive, as detected by an FDA-approved 
test, in combination with standard cytarabine 
and daunorubicin induction and cytarabine 
consolidation.
Multi-targeted protein kinase inhibitor  Novartis  Pharmaceuticals (132]
7
Durvalumab 
(Imfi nzi)
For treatment of patients with locally advanced 
or metastatic urothelial carcinoma who 
experience disease progression during or 
after platinumcontaining chemotherapy or 
who experience disease progression within 12 
months of neoadjuvant or adjuvant treatment 
with platinum-containing chemotherapy
 Blocks the interaction of programmed cell 
death ligand 1 (PD-L1) with the PD-1 and CD80 
(B7.1
 Medimmune/AstraZeneca [133]
8
Rituximab and 
hyaluronidase 
human (Rituxan 
Hycela)
For adult patients with follicular lymphoma, 
diffuse large B-cell lymphoma, and chronic 
lymphocytic leukemia
Three major independent mechanisms are 
1. Antibody dependent cellular cytotoxicity 
2. Complement mediated cytotoxicity 3. 
Apoptosis, subst panel illustrates a schematic 
view of CD20 structure and rituximab 
IDEC Pharmaceuticals  [134]
9 Neratinib (Nerlynx)
For extended adjuvant treatment of adult 
patients with early-stage HER2-overexpressed/
amplifi ed breast cancer, to follow adjuvant 
trastuzumab-based therapy
Dual inhibitor of the human epidermal growth 
factor receptor 2 (Her2) and epidermal growth 
factor receptor (EGFR) kinases 
 developed 
by Wyeth; Pfi zer continued 
development up to Phase III in 
breast cancer, and licensed it 
to Puma Biotechnology 
[135-137]
10
Daunorubicin and 
cytarabine (Vyxeos)
For treatment of adults with newly 
diagnosed therapy-related AML or AML with 
myelodysplasia-related changes, two types of 
AML that have a poor prognosis.
Blocking the function of topoisomerase II Ohio State University [138]
11 Enasidenib (Idhifa)
For treatment of adult patients with 
relapsed or refractory AML with an isocitrate 
dehydrogenase-2 mutation as detected by an 
FDA-approved test.
Inhibitor of IDH2 Agios Pharmaceuticals [139]
12
Inotuzumab 
ozogamicin 
(Besponsa)
For treatment of adults with relapsed or 
refractory B-cell precursor ALL.
 Binds to CD22 receptor  Celltech and Wyeth Pfi zer [140]
13
Tisagenlecleucel 
(Kymriah)
For treatment of patients ≤ 25 years of age 
with B-cell precursor ALL that is refractory or in 
second or later relapse
Treat B cell acute lymphoblastic leukemia
University of Pennsylvania; 
and  Novartis 
[141]
14
Abemaciclib 
(Verzenio)
In combination with fulvestrant for women 
with HR-positive, HER2-negative advanced 
or metastatic breast cancer with disease 
progression after endocrine therapy.
 CDK inhibitor selective for CDK4 and CDK6 Eli Lilly [142]
15
Bevacizumab-awwb 
(Mvasi)
Approved as a biosimilar to bevacizumab 
(Avastin), bevacizumab-awwb is the fi rst 
biosimilar approved in the United States for the 
treatment of cancer.
 Blocks angiogenesis by inhibiting vascular 
endothelial growth factor A (VEGF-A) 
Genentech [143]
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16 Copanlisib (Aliqopa)
For treatment of adult patients with relapsed 
follicular lymphoma who have received at least 
two prior systemic therapies
 Inhibitor of phosphatidylinositol-3-
kinase (PI3K) 
 Bayer [144]
17
Gemtuzumab 
ozogamicin 
(Mylotarg)
Newly diagnosed CD33-positive AML in adults 
and for treatment of relapsed or refractory 
CD33-positive AML in adults and pediatric 
patient’s ≥ 2 years of age. May be used in 
combination with daunorubicin and cytarabine 
for adults with newly diagnosed AML or as 
a stand-alone treatment of certain adult and 
pediatric patients.
Targets the membrane antigen CD33 Celltech and Wyeth [145]
18
Axicabtagene 
ciloleucel (Yescarta)
For treatment of adult patients with relapsed 
or refractory large B-cell lymphoma after two or 
more lines of systemic therapy.
An anti-CD19  chimeric antigen receptor  (CAR 
T) cell  
Kite Pharma California [146]
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